Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of ONO-4538 in Pan-Tumor Patients Continuing Treatment
NCT04566380Phase 2Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2020
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of nivolumab in cancer, sponsored by Ono Pharmaceutical. Started Sep 2020; status: recruiting.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04566380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04566380.